The direct cost of epilepsy in Cuba. A study in outpatients [1];Coste directo de la epilepsia en Cuba. Estudio en consulta externa

Revista de Neurologia

Volumn 41, Issue 6, 2005, Pages 379-381

  González Pal, Salvador ^a,b   Quintana Mendoza, J ^a   Roman Lopez J R ^a   Fernandez Perez J E ^a  

^a HOSPITAL PSIQUIÁTRICO DE LA HABANA   (Cuba)

^b NONE   (Cuba)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAMAZEPINE; CLONAZEPAM; PHENOBARBITAL; PHENYTOIN; VALPROATE MAGNESIUM; VALPROIC ACID; ANTICONVULSIVE AGENT;

COMPUTER ASSISTED TOMOGRAPHY; CONSULTATION; CUBA; DRUG COST; ECONOMIC ASPECT; ELECTROENCEPHALOGRAM; EPILEPSY; HEALTH CARE COST; HUMAN; LETTER; NUCLEAR MAGNETIC RESONANCE; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TABLET FORMULATION; ECONOMICS; OUTPATIENT;

ANTICONVULSANTS; CUBA; EPILEPSY; HEALTH CARE COSTS; HUMANS; OUTPATIENTS;

EID: 32944471298     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.4106.2004581     Document Type: Letter

References (23)

1. Argumosa A, JL Herranz. Aspectos económicos de la epilepsia. Rev Neurol 2000; 30 (Supl 1): S154-60.
2. Begley CE, Annegers JF, Lairson DR, Reynolds TF, Hauser WA. The lifetime cost of epilepsy in the United States: a model based on incidence and prognosis. In Beran RG, Paclatko C, eds. Cost of epilepsy: proceedings of the 20th International Epilepsy Congress. Wehr-Baden: Ciba-Geigy Verlag; 1993. p. 17-26.
3. Banks GK, Regan KJ, Beran RG. The prevalence and direct cost of epilepsy in Australia. In Beran RG, Paclatko C, eds. Cost of epilepsy: proceedings of the 20th International Epilepsy Congress. Wehr-Baden: Ciba-Geigy Verlag; 1993. p. 39-48.
4. Beran R, Banks GK. Idirect cost of epilepsy in Australia. In Beran RG, Paclatko C, eds. Cost of epilepsy: proceedings of the 20th International Epilepsy Congress. Wehr-Baden: Ciba-Geigy Verlag; 1993. p. 49-54.
5. Chandra B. Economic aspects of epilepsy in Indonesia. In Beran RG, Pachilacko C, eds. Cost of epilepsy: proceedings of the 20th International Epilepsy Congress. Wehr-Baden: Ciba-Geigy Verlag; 1993. p. 75-82.
6. Silfvenius H, Lindholm L, Säisä J, Olivercrona M, Uverbrant P, Christianson SA. Cost of savings from paediatrics epilepsy surgery: a Swedish study. In Beran RG, Paclatko C, eds. Cost of epilepsy: proceedings of the 20th International Epilepsy Congress. Wehr-Baden: Ciba-Geigy Verlag; 1993. p. 83-106.
7. Cockerrell OC, Hart YM, Sander JW, Shorvon SD. The cost of epilepsy in the United Kingdom. In Beran RG, Pachlatko C, eds. Cost of epilepsy: proceedings of the 20th International Epilepsy Congress. Wehr-Baden: Ciba-Geigy Verlag; 1993. p. 27-38.
8. Geessner U, Sagmeister M, Horisberg B. The economic impact of epilepsy in Switerland. In Beran RG, Pachlatko C, eds. Cost of epilepsy: proceedings of the 20th International Epilepsy Congress. Wehr-Baden: Ciba-Geigy Verlag; 1993. p. 67-74.
9. Pachlatko C. The relevance of health economics to epilepsy care. Epilepsia 1999; 40 (Suppl 8): S3-7.
10. Placencia M. Incidencia, prevalencia y magnitud global de la epilepsia en América latina y el Caribe. En Campos MG, Kanner AM. Epilepsias. Diagnóstico y tratamiento. Santiago, Buenos Aires, Montevideo: Editorial Mediterráneo; 2004.
11. Gerrini R, Battini R, Ferrari AR, Veggiotti P, Besana D, Gobbi Get al. The costs of childhood epilepsy in Italy: comparative findings from three health care settings. Epilepsia 2001; 42: 641-6.
12. Jakoby A, Buck D, Baker G, McNamme P, Graham-Jones S, Chadwick D, et al. Uptake and costs of care for epilepsy findings from a UK regional study. Epilepsia 1998; 39: 776-86.
13. Van Hout B, Gagnon D, Souetre E, Ried S, Remy C, Baker G, et al. Relationship between seizure frequency and costs and quality of life of outpatients with partial epilepsy in France, Germany, and the United Kingdon. Epilepsia 1997; 38: 1221-6.
14. Banks GK, Beran RG, Regan KJ. The prevalence and cost of epilepsy in Australia. Epilepsia 1993; 34 (Suppl 2): S146.
15. González-Pal S, Quintana J, Fabelo R, Rivero L, González C. Cambios en el comportamiento psicosocial de un grupo de pacientes con epilepsia y psicosis crónica después de un año de tratamiento con lamotrigina. URL: http://www.psiquiatria.com/psiquiatria/vol3num1/art_3.htm. Fecha última consulta: 01.04.99.
16. González-Pal S, Quintana-Mendoza J, Fabelo-Roche R, Rivero-Lapuente L. Uso de lamotrigina en la readaptación psicosocial del paciente con epilepsia. Rev Neurol 2000; 31: 21-6.
17. Heaney DC, Shorvon SD, Sander JW. An economic apparaisal of carbamazepine, lamotrigine, phenytoin and valproate as initial treatment in adults with newly diagnosed epilepsy. Epilepsia 1998; 39 (Suppl 3): S19-25.
18. Shakespeare A, Simeon G. Economic analysis of epilepsy treatment: a cost minimization analysis comparing carbamazepine an lamotrigine in the UK. Seisure 1998; 7: 119-25.
19. Tetto A, Manzoni P, Milloul A, Beghi F, Garantini C, Tartara A, et al. The costs of epilepsy in Italy: a prospective cost of illness study in referral patients with disease of different severity. Epilepsy Res 2002; 48: 207-16.
20. Begley CE, Beghi E. The economic cost of epilepsy: a review of the literature. Epilepsia 2002; 43 (Suppl 4): S3-9.
21. Murray CJ, López AD. Global comparative assessments in the health sector: disease burden, expendidures and intervention packages. Geneva: World Health Organization; 1994.
22. Pato-Pato A, Cimas-Hernando I, Lorenzo González JR, Vadillo-Olmo FJ. Impacto económico de la epilepsia. Rev Neurol 2004; 39: 450-3.
23. EUCARE. European white paper on epilepsy. Bruxelles: EUCARE; 2002.